2nd Quarter - Report
OREXIGEN THERAPEUTICS, INC. for OREXIGEN THERAPEUTICS, INC.
Client
Income
—
Expenses
$115,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislative and regulatory matters related to the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) with a focus on the regulation of novel therapeutics for the treatment of obesity.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN BRENNAN | — |
| PAUL KIM | — |
| SUZANNE MARIE MCDONALD | — |
| HEATHER DINEEN TURNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.